Bhatt A. Evolution of clinical research: a history before and beyond James Lind. Perspect Clin Res. 2010;1:6–10. https://doi.org/10.4103/2229-3485.71839.

Article  PubMed  PubMed Central  Google Scholar 

Charlesworth CJ, Smit E, Lee DSH, Alramadhan F, Odden MC. Polypharmacy among adults aged 65 years and older in the United States: 1988–2010. J Gerontol A Biol Sci Med Sci. 2015;70:989–95. https://doi.org/10.1093/gerona/glv013.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab. 2019;10:204201881984469. https://doi.org/10.1177/2042018819844694.

Article  Google Scholar 

Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33:1635–701. https://doi.org/10.1093/eurheartj/ehs092.

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. J Hypertens. 2015;33:195–211. https://doi.org/10.1097/hjh.0000000000000447.

Article  CAS  PubMed  Google Scholar 

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23. https://doi.org/10.1016/s0140-6736(05)17741-1.

Article  PubMed  Google Scholar 

Kotseva K, Wood D, De Bacquer D, De Backer G, Rydén L, Jennings C, Gyberg V, Amouyel P, Bruthans J, Castro Conde A, Cífková R, Deckers JW, De Sutter J, Dilic M, Dolzhenko M, Erglis A, Fras Z, Gaita D, Gotcheva N, Goudevenos J, Heuschmann P, Laucevicius A, Lehto S, Lovic D, Miličić D, Moore D, Nicolaides E, Oganov R, Pajak A, Pogosova N, Reiner Z, Stagmo M, Störk S, Tokgözoğlu L, Vulic D. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23:636–48. https://doi.org/10.1177/2047487315569401.

Article  PubMed  Google Scholar 

Yoon S, Fryar C, Carroll M. Hypertension prevalence and control among adults: United States, 2011–2014. NCHS Data Brief, no 220. Hyattsville, MD: National Center for Health Statistics. 2016. https://www.cdc.gov/nchs/data/data-briefs/db220.htm. Accessed 18 Dec 2016.

Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Marešová V, White CMJ, Petrák O, Gulsin GS, Patel V, Rosa J, Cole R, Zelinka T, Holaj R, Kinnell A, Smith PR, Thompson JR, Squire I, Widimský J, Samani NJ, Williams B, Tomaszewski M. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 2017;69:1113–20. https://doi.org/10.1161/hypertensionaha.116.08729.

Article  CAS  PubMed  Google Scholar 

Derington CG, King JB, Herrick JS, Shimbo D, Kronish IM, Saseen JJ, Muntner P, Moran AE, Bress AP. Trends in antihypertensive medication monotherapy and combination use among US adults, national health and nutrition examination survey 2005–2016. Hypertension. 2020;75:973–81. https://doi.org/10.1161/hypertensionaha.119.14360.

Article  CAS  PubMed  Google Scholar 

Ritchey M, Tsipas S, Loustalot F, Wozniak G. Use of pharmacy sales data to assess changes in prescription- and payment-related factors that promote adherence to medications commonly used to treat hypertension, 2009 and 2014. PLoS ONE. 2016;11: e0159366. https://doi.org/10.1371/journal.pone.0159366.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mensah GA, Bakris G. Treatment and control of high blood pressure in adults. Cardiol Clin. 2010;28:609–22. https://doi.org/10.1016/j.ccl.2010.08.002.

Article  PubMed  Google Scholar 

Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16. https://doi.org/10.1056/NEJMoa1511939.

Article  CAS  PubMed  Google Scholar 

Pietrzak K, Isreb A, Alhnan MA. A flexible-dose dispenser for immediate and extended release 3D printed tablets. Eur J Pharm Biopharm. 2015;96:380–7. https://doi.org/10.1016/j.ejpb.2015.07.027.

Article  CAS  PubMed  Google Scholar 

Chow CK, Atkins ER, Billot L, Chalmers J, Hillis GS, Hay P, Neal B, Nelson M, Patel A, Reid CM, Schlaich M, Usherwood T, Webster R, Rodgers A. Ultra-low-dose quadruple combination blood pressure–lowering therapy in patients with hypertension: the QUARTET randomized controlled trial protocol. Am Heart J. 2021;231:56–67. https://doi.org/10.1016/j.ahj.2020.09.017.

Article  CAS  PubMed  Google Scholar 

Wang N, Salam A, Webster R, de Silva A, Guggilla R, Stepien S, Mysore J, Billot L, Jan S, Maulik PK, Naik N, Selak V, Thom S, Prabhakaran D, Patel A, Rodgers A. Association of low-dose triple combination therapy with therapeutic inertia and prescribing patterns in patients with hypertension: a secondary analysis of the TRIUMPH trial. JAMA Cardiol. 2020;5:1219–26. https://doi.org/10.1001/jamacardio.2020.2739.

Article  PubMed  PubMed Central  Google Scholar 

Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399–407. https://doi.org/10.1161/hypertensionaha.109.139816.

Article  CAS  PubMed  Google Scholar 

Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021;77:692–705. https://doi.org/10.1161/hypertensionaha.120.15781.

Article  CAS  PubMed  Google Scholar 

Chang TE, Ritchey MD, Park S, Chang A, Odom EC, Durthaler J, Jackson SL, Loustalot F. National rates of nonadherence to antihypertensive medications among insured adults with hypertension, 2015. Hypertension. 2019;74:1324–32. https://doi.org/10.1161/hypertensionaha.119.13616.

Article  CAS  PubMed  Google Scholar 

• World Health Organization. World Health Organization model list of essential medicines, 21st list, 2019. Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization; 2019. Findings from this study suggest that polypill lowers CV events in the post-myocardial infarction group.

Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011;124:128–35. https://doi.org/10.1016/j.amjmed.2010.08.007.

Article  CAS  PubMed  Google Scholar 

Shirley M, McCormack PL. Perindopril/Amlodipine (Prestalia®): a review in hypertension. Am J Cardiovasc Drugs. 2015;15:363–70. https://doi.org/10.1007/s40256-015-0144-1.

Article  CAS  PubMed  Google Scholar 

• Derington CG, Cohen JB, Bress AP. Restoring the upward trend in blood pressure control rates in the United States: a focus on fixed-dose combinations. J Hum Hypertens. 200;34:617–23. https://doi.org/10.1038/s41371-020-0340-6. Findings from this study suggest that polypill lowers CV events in the post-myocardial infarction group.

U.S. Food & Drug Administration. High blood pressure. https://www.fda.gov/consumers/free-publications-women/high-blood-pressure#Combination_Medicines.

Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, Tu W. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385:2507–19. https://doi.org/10.1056/nejmoa2110730.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Agarwal R, Cramer AE, Balmes-Fenwick M, Sinha AD, Ouyang F, Tu W. Design and baseline characteristics of the chlorthalidone in chronic kidney disease (CLICK) trial. Am J Nephrol. 2020;51:542–52. https://doi.org/10.1159/000508700.

Article  CAS  PubMed  Google Scholar 

Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The adverse experience committee; and the multicenter diltiazem postinfarction research group. Circulation. 1991;83:52–60. https://doi.org/10.1161/01.cir.83.1.52.

Collaboration TPS. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13. https://doi.org/10.1016/s0140-6736(02)11911-8.

Article  Google Scholar 

Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52. https://doi.org/10.1016/s0140-6736(04)17018-9.

Article  PubMed  Google Scholar 

Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419. https://doi.org/10.1136/bmj.326.7404.1419.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muñoz D, Uzoije P, Reynolds C, Miller R, Walkley D, Pappalardo S, Tousey P, Munro H, Gonzales H, Song W, White C, Blot WJ, Wang TJ. Polypill for cardiovascular disease prevention in an underserved population. N Engl J Med. 2019;381:1114–23. https://doi.org/10.1056/nejmoa1815359.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, Ostovaneh MR, Nateghi A, Majed M, Navabakhsh B, Merat S, Pourshams A, Nalini M, Malekzadeh F, Sadeghi M, Mohammadifard N, Sarrafzadegan N, Naemi-Tabiei M, Fazel A, Brennan P, Etemadi A, Boffetta P, Thomas N, Marshall T, Cheng KK, Malekzadeh R. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394:672–83. https://doi.org/10.1016/s0140-6736(19)31791-x.

Article  CAS  PubMed  Google Scholar 

Webster R, Bullen C, Patel A, Selak V, Stepien S, Thom S, Rodgers A. Impact of switching to polypill based therapy by baseline potency of medication: post-hoc analysis of the SPACE Collaboration dataset. Int J Cardiol. 2017;249:443–7. https://doi.org/10.1016/j.ijcard.2017.09.162.

Article  PubMed  Google Scholar 

•• Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, López-Jaramillo P, Yusoff K, Santoso A, Gamra H, Talukder S, Christou C, Girish P, Yeates K, Xavier F, Dagenais G, Rocha C, McCready T, Tyrwhitt J, Bosch J, Pais P. Polypill with or without aspirin in persons without cardiovascular disease. N Engl J Med. 2021;384:216–28. https://doi.org/10.1056/nejmoa2028220. Findings from this study suggest that polypill lowers CV events in the intermediate CV risk group.

•• Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, Sanchez PL, Marin Ortuño F, Vazquez Rodriguez JM, Domingo-Fernández A, Lozano I, Roncaglioni MC, Baviera M, Foresta A, Ojeda-Fernandez L, Colivicchi F, Di Fusco SA, Doehner W, Meyer A, Schiele F, Ecarnot F, Linhart A, Lubanda J-C, Barczi G, Merkely B, Ponikowski P, Kasprzak M, Fernandez Alvira JM, Andres V, Bueno H, Collier T, Van de Werf F, Perel P, Rodriguez-Manero M, Alonso Garcia A, Proietti M, Schoos MM, Simon T, Fernandez Ferro J, Lopez N, Beghi E, Bejot Y, Vivas D, Cordero A, Ibañez B, Fuster V. Polypill strategy in secondary cardiovascular prevention. N Engl J Med. 2022;387:967–77. https://doi.org/10.1056/nejmoa2208275. Findings from this study suggest that polypill lowers CV events in the post-myocardial infarction group.

Zhang ZY, Yu YL, Asayama K, Hansen TW, Maestre GE, Staessen JA. Starting antihypertensive drug treatment with combination therapy: controversies in hypertension — con side of the argument. Hypertension. 2021;77:788–98. https://doi.org/10.1161/hypertensionaha.120.12858.Erratum.In:Hypertension.2021Apr;77(4):e44.